Want to see SER full AI Analyst Report?
SER Stock Chart & Stats
$2.70
-$0.02(-0.96%)
At close: 4:00 PM EDT
$2.70
-$0.02(-0.96%)
Day’s Range― - ―
52-Week Range$1.22 - $5.83
Previous CloseN/A
Volume44.32K
Average Volume (3M)79.71K
Market Cap
$49.78M
Enterprise Value$11.97M
Total Cash (Recent Filing)$23.02M
Total Debt (Recent Filing)$3.21M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Nov 18, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume127,673
30 Day Avg. Volume79,711
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.69
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$9.50Price Target Upside251.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
POZ Drug-delivery PlatformThe POZ platform gives Serina a defined technology focus for extending drug release and improving pharmacokinetics, tolerability, and efficacy. If development succeeds, the platform could support multiple candidates and applications rather than relying on a single product opportunity.
Low Financial LeverageVery low debt reduces fixed financial obligations and preserves flexibility while Serina funds research and development. The modest leverage profile means the company is not currently burdened by substantial interest or repayment requirements, although operating losses remain a separate constraint.
Experienced Commercial GovernanceAdding a director with biopharma commercial and business-development experience strengthens oversight as Serina advances SER-252 and its POZ platform. This expertise may improve decision-making around clinical development, partnerships, commercialization planning, and capital strategy over the medium term.
Bears Say
No Current Revenue ScaleThe absence of current revenue indicates Serina remains pre-commercial and lacks an operating sales base to fund development internally. Deep losses also show that the business has not yet converted its platform and candidates into sustainable earnings, leaving results dependent on future milestones.
Persistent Cash BurnLarge negative operating and free cash flow means research and corporate expenses are consuming substantial cash rather than generating funding. Continued burn can shorten the company’s financial runway and constrain development plans unless operating performance improves or additional capital is secured.
Potential Equity DilutionThe flexible equity facility provides funding access but can expand the share count as new shares are issued, creating dilution for existing holders. The financing’s use for working capital and general purposes also highlights ongoing dependence on external capital while the company remains loss-making.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.22 and its highest was $5.83 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $49.78M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 43 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.466 by -$0.084.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 25,400,473 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.466. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (251.85% Upside)
$9.50 (251.85% Upside)
Insider Transactions
Bought Shares
Worth $2.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
188.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$9.50
▲(251.85% Upside)
Technical Analysis
Ownership Overview
34.84% Insiders
0.78% Mutual Funds
4.10% Other Institutional Investors
59.57% Public Companies and
Individual Investors